Cat. No.: HY-13578

Copy Link Print Information

Brivudine

(Synonyms: Bromovinyldeoxyuridine; BVDU)

2 Cited Publications

Customer Review

Based on 2 publication(s) in Google Scholar

Brivudine is a thymidine analogue with antiviral activity, indicated for the early treatment of acute herpes zoster.

For research use only. We do not sell to patients.

Purity: 99.72%
CAS No.: 69304-47-8
Formula: C₁₁H₁₃BrN₂O₅
Molecular Weight:333.14

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

Brivudine Chemical Structure

CAS No.: 69304-47-8

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (2)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

Brivudine is a thymidine analogue with antiviral activity, indicated for the early treatment of acute herpes zoster.

Cellular Effect

Cell Line	Type	Value	Description	References
A549	EC₅₀	>100 μM Compound: 6; BVDU; Brivudin	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTS assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTS assay	[PMID: 27032331]
BC-3	IC₅₀	>15 μM Compound: BVDU	Cytotoxicity against Kaposi's sarcoma-associated herpesvirus infected BC3 cells after 120 hrs by MTT assay Cytotoxicity against Kaposi's sarcoma-associated herpesvirus infected BC3 cells after 120 hrs by MTT assay	[PMID: 17402726]
C3H	EC₅₀	>100 μg/mL Compound: brivudin	Antiviral activity against MSV in mouse C3H cells assessed as inhibition of virus-induced transformation after 6 days Antiviral activity against MSV in mouse C3H cells assessed as inhibition of virus-induced transformation after 6 days	[PMID: 17298047]
CCRF-CEM	EC₅₀	>50 μM Compound: BVDU	Concentration required to inhibit human immunodeficiency virus-1 (strain IIIb) induced cytopathogenicity in CEM cells by 50% Concentration required to inhibit human immunodeficiency virus-1 (strain IIIb) induced cytopathogenicity in CEM cells by 50%	[PMID: 16000005]
CCRF-CEM	EC₅₀	>50 μM Compound: BVDU	Concentration required to inhibit human immunodeficiency virus-1 (strain ROD) induced cytopathogenicity in CEM cells by 50% Concentration required to inhibit human immunodeficiency virus-1 (strain ROD) induced cytopathogenicity in CEM cells by 50%	[PMID: 16000005]
CCRF-CEM	EC₅₀	>100 μg/mL Compound: brivudin	Antiviral activity against HIV1 3B in human CEM cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against HIV1 3B in human CEM cells assessed as inhibition of virus-induced cytopathicity	[PMID: 17298047]
CCRF-CEM	EC₅₀	>100 μg/mL Compound: brivudin	Antiviral activity against HIV2 ROD in human CEM cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against HIV2 ROD in human CEM cells assessed as inhibition of virus-induced cytopathicity	[PMID: 17298047]
CCRF-CEM	IC₅₀	>100 μM Compound: BVdU	Cytostatic activity against human CD4-positive CEM cells after 3 days by cell counting method Cytostatic activity against human CD4-positive CEM cells after 3 days by cell counting method	[PMID: 27818111]
CCRF-CEM	IC₅₀	100 μM Compound: BVdU	Cytostatic activity against thymidine kinase deficient human CD4-positive CEM cells after 3 days by cell counting method Cytostatic activity against thymidine kinase deficient human CD4-positive CEM cells after 3 days by cell counting method	[PMID: 27818111]
CCRF-CEM	CC₅₀	207 μM Compound: 1f; BVdU	Cytotoxicity in human CEM/0 cells assessed as reduction in cell viability incubated for 4 to 5 days Cytotoxicity in human CEM/0 cells assessed as reduction in cell viability incubated for 4 to 5 days	[PMID: 32515595]
CCRF-HSB-2	IC₅₀	>100 μg/mL Compound: 7	Compound was evaluated for the cytotoxicity against human T-cell leukemia, CCRF-HSB-2 by using MTT assay. Compound was evaluated for the cytotoxicity against human T-cell leukemia, CCRF-HSB-2 by using MTT assay.	[PMID: 10206544]
DG-75	IC₅₀	>15 μM Compound: BVDU	Cytotoxicity against DG75 cells after 120 hrs by MTT assay Cytotoxicity against DG75 cells after 120 hrs by MTT assay	[PMID: 17402726]
E6SM	EC₅₀	>400 μg/mL Compound: BVDU	Inhibitory activity against HSV-2 (196) replication in E6SM cell cultures of human embryonic skin-muscle Inhibitory activity against HSV-2 (196) replication in E6SM cell cultures of human embryonic skin-muscle	[PMID: 12459010]
E6SM	EC₅₀	>400 μg/mL Compound: BVDU	Inhibitory activity against vesicular stomatitis virus (VSV) replication in E6SM cell cultures of human embryonic skin-muscle Inhibitory activity against vesicular stomatitis virus (VSV) replication in E6SM cell cultures of human embryonic skin-muscle	[PMID: 12459010]
E6SM	EC₅₀	0.026 μg/mL Compound: BVDU	Inhibitory activity against HSV-1 (F) replication in E6SM cell cultures of human embryonic skin-muscle Inhibitory activity against HSV-1 (F) replication in E6SM cell cultures of human embryonic skin-muscle	[PMID: 12459010]
E6SM	EC₅₀	0.026 μg/mL Compound: BVDU	Inhibitory activity against HSV-1 (KOS) replication in E6SM cell cultures of human embryonic skin-muscle Inhibitory activity against HSV-1 (KOS) replication in E6SM cell cultures of human embryonic skin-muscle	[PMID: 12459010]
E6SM	EC₅₀	0.026 μg/mL Compound: BVDU	Inhibitory activity against HSV-1 (McIntyre) replication in E6SM cell cultures of human embryonic skin-muscle Inhibitory activity against HSV-1 (McIntyre) replication in E6SM cell cultures of human embryonic skin-muscle	[PMID: 12459010]
E6SM	EC₅₀	1.9 μg/mL Compound: BVDU	Inhibitory activity against vaccinia virus (VV) replication in E6SM cell cultures of human embryonic skin-muscle Inhibitory activity against vaccinia virus (VV) replication in E6SM cell cultures of human embryonic skin-muscle	[PMID: 12459010]
E6SM	EC₅₀	240 μg/mL Compound: BVDU	Inhibitory activity against HSV-2 (G) replication in E6SM cell cultures of human embryonic skin-muscle Inhibitory activity against HSV-2 (G) replication in E6SM cell cultures of human embryonic skin-muscle	[PMID: 12459010]
E6SM	EC₅₀	240 μg/mL Compound: BVDU	Inhibitory activity against HSV-2 (Lyons) replication in E6SM cell cultures of human embryonic skin-muscle Inhibitory activity against HSV-2 (Lyons) replication in E6SM cell cultures of human embryonic skin-muscle	[PMID: 12459010]
E6SM	EC₅₀	240 μg/mL Compound: BVDU	Inhibitory activity against TK-deficient HSV-1 (KOS) replication in E6SM cell cultures of human embryonic skin-muscle Inhibitory activity against TK-deficient HSV-1 (KOS) replication in E6SM cell cultures of human embryonic skin-muscle	[PMID: 12459010]
E6SM	EC₅₀	>400 μg/mL Compound: brivudin	Effective concentration required to reduce vaccinia virus plaque formation by 50% in E6SM Cell Culture Effective concentration required to reduce vaccinia virus plaque formation by 50% in E6SM Cell Culture	[PMID: 15481985]
E6SM	EC₅₀	0.01 μg/mL Compound: brivudin	Effective concentration required to reduce HSV-1 strain KOS virus plaque formation by 50% in E6SM Cell Culture Effective concentration required to reduce HSV-1 strain KOS virus plaque formation by 50% in E6SM Cell Culture	[PMID: 15481985]
E6SM	EC₅₀	16 μg/mL Compound: brivudin	Effective concentration required to reduce HSV-1 strain KOS ACV virus plaque formation by 50% in E6SM Cell Culture Effective concentration required to reduce HSV-1 strain KOS ACV virus plaque formation by 50% in E6SM Cell Culture	[PMID: 15481985]
E6SM	EC₅₀	80 μg/mL Compound: brivudin	Effective concentration required to reduce HSV-2 strain G virus plaque formation by 50% in E6SM Cell Culture Effective concentration required to reduce HSV-2 strain G virus plaque formation by 50% in E6SM Cell Culture	[PMID: 15481985]
E6SM	EC₅₀	>400 μg/mL Compound: brivudin	Antiviral activity against VSV in E6SM cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against VSV in E6SM cells assessed as inhibition of virus-induced cytopathicity	[PMID: 17298047]
E6SM	EC₅₀	0.02 μg/mL Compound: brivudin	Antiviral activity against HSV1 KOS in E6SM cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against HSV1 KOS in E6SM cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17518459]
E6SM	EC₅₀	0.2 μg/mL Compound: brivudin	Antiviral activity against Vaccinia virus in E6SM cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against Vaccinia virus in E6SM cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17518459]
E6SM	EC₅₀	150 μg/mL Compound: brivudin	Antiviral activity against HSV2 G in E6SM cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against HSV2 G in E6SM cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17518459]
E6SM	EC₅₀	40 μg/mL Compound: brivudin	Antiviral activity against thymidine kinase deficient HSV1 VMW1837 in E6SM cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against thymidine kinase deficient HSV1 VMW1837 in E6SM cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17518459]
E6SM	EC₅₀	40 μg/mL Compound: brivudin	Antiviral activity against thymidine kinase-deficient HSV1 B2006 in E6SM cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against thymidine kinase-deficient HSV1 B2006 in E6SM cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17518459]
E6SM	EC₅₀	>400 μg/mL Compound: Brivudin	Antiviral activity against TK-deficient acyclovir-resistant HSV1 KOS infected in human E6SM cell assessed as inhibition of virus-induced cytopathicity Antiviral activity against TK-deficient acyclovir-resistant HSV1 KOS infected in human E6SM cell assessed as inhibition of virus-induced cytopathicity	[PMID: 20377249]
E6SM	EC₅₀	>400 μg/mL Compound: Brivudin	Antiviral activity against VSV infected in human E6SM cell assessed as inhibition of virus-induced cytopathicity Antiviral activity against VSV infected in human E6SM cell assessed as inhibition of virus-induced cytopathicity	[PMID: 20377249]
E6SM	EC₅₀	0.384 μg/mL Compound: Brivudin	Antiviral activity against HSV1 KOS infected in human E6SM cell assessed as inhibition of virus-induced cytopathicity Antiviral activity against HSV1 KOS infected in human E6SM cell assessed as inhibition of virus-induced cytopathicity	[PMID: 20377249]
E6SM	EC₅₀	80 μg/mL Compound: Brivudin	Antiviral activity against HSV2 G infected in human E6SM cell assessed as inhibition of virus-induced cytopathicity Antiviral activity against HSV2 G infected in human E6SM cell assessed as inhibition of virus-induced cytopathicity	[PMID: 20377249]
E6SM	EC₅₀	9.6 μg/mL Compound: Brivudin	Antiviral activity against Vaccina virus infected in human E6SM cell assessed as inhibition of virus-induced cytopathicity Antiviral activity against Vaccina virus infected in human E6SM cell assessed as inhibition of virus-induced cytopathicity	[PMID: 20377249]
E6SM	CC₅₀	>400 μg/mL Compound: brivudin	Cytotoxic concentration required to cause microscopically detectable alteration of normal cell morphology of E6SM cells Cytotoxic concentration required to cause microscopically detectable alteration of normal cell morphology of E6SM cells	[PMID: 8709116]
HEL	IC₅₀	>100 μM Compound: BVDU	The compound was tested for cytotoxic concentration required to reduce human embryonic lung cell growth by 50% The compound was tested for cytotoxic concentration required to reduce human embryonic lung cell growth by 50%	[PMID: 10411487]
HEL	IC₅₀	>50 μM Compound: BVDU	The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against Varicella zoster TK-(deficient) 07/1 strain The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against Varicella zoster TK-(deficient) 07/1 strain	[PMID: 10411487]
HEL	IC₅₀	>50 μM Compound: BVDU	The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against Varicella zoster TK-(deficient) YS/R strain The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against Varicella zoster TK-(deficient) YS/R strain	[PMID: 10411487]
HEL	IC₅₀	>50 μM Compound: BVDU	Minimum cytotoxic concentration that causes a microscopically detectable alteration of cell morphology in human embryonic lung cells Minimum cytotoxic concentration that causes a microscopically detectable alteration of cell morphology in human embryonic lung cells	[PMID: 10411487]
HEL	IC₅₀	0.001 μM Compound: BVDU	The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against Varicella zoster TK+OKA strain The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against Varicella zoster TK+OKA strain	[PMID: 10411487]
HEL	IC₅₀	0.005 μM Compound: BVDU	The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against Varicella zoster TK+YS strain The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against Varicella zoster TK+YS strain	[PMID: 10411487]
HEL	IC₅₀	>400 μM Compound: 6 (BVDU)	Compound was evaluated for the anti-viral activity against HEL cells Compound was evaluated for the anti-viral activity against HEL cells	[PMID: 10579812]
HEL	CC₅₀	>400 μM Compound: 6 (BVDU)	cytostatic concentration required to reduce the HEL cell number by 50%. after 5 days in the absence of virus cytostatic concentration required to reduce the HEL cell number by 50%. after 5 days in the absence of virus	[PMID: 11150169]
HEL	EC₅₀	>150 μM Compound: 6 (BVDU)	Evaluated for the anti-VZV, the concentration of compounds in uM required to reduce VZVTK-07 ( thymidine kinase-deficient strain ) plaque formation after 5 days in HEL cell cultures compared to untreated controls. Evaluated for the anti-VZV, the concentration of compounds in uM required to reduce VZVTK-07 ( thymidine kinase-deficient strain ) plaque formation after 5 days in HEL cell cultures compared to untreated controls.	[PMID: 11150169]
HEL	EC₅₀	>150 μM Compound: 6 (BVDU)	Evaluated for the anti-VZV, the concentration of compounds in uM required to reduce VZVTK-YS-R ( thymidine kinase-deficient strain ) plaque formation after 5 days in HEL cell cultures compared to untreated controls. Evaluated for the anti-VZV, the concentration of compounds in uM required to reduce VZVTK-YS-R ( thymidine kinase-deficient strain ) plaque formation after 5 days in HEL cell cultures compared to untreated controls.	[PMID: 11150169]
HEL	EC₅₀	0.003 μM Compound: 6 (BVDU)	Evaluated for the anti-VZV activity, the concentration of compounds in uM required to reduce VZV OKA Plaque formation after 5 days in HEL cell cultures compared to untreated controls. Evaluated for the anti-VZV activity, the concentration of compounds in uM required to reduce VZV OKA Plaque formation after 5 days in HEL cell cultures compared to untreated controls.	[PMID: 11150169]
HEL	EC₅₀	0.003 μM Compound: 6 (BVDU)	Evaluated for the anti-VZV activity, the concentration of compounds in uM required to reduce VZV TS plaque formation after 5 days in HEL cell cultures compared to untreated controls. Evaluated for the anti-VZV activity, the concentration of compounds in uM required to reduce VZV TS plaque formation after 5 days in HEL cell cultures compared to untreated controls.	[PMID: 11150169]
HEL	CC₅₀	>200 μg/mL Compound: Brivudin	Cytotoxic concentration reducing HEL cell growth by 50%. Cytotoxic concentration reducing HEL cell growth by 50%.	[PMID: 12217359]
HEL	EC₅₀	>150 μM Compound: brivudin	Effective concentration required to reduce CMV AD169 strain virus plaque formation by 50% in HEL cell culture Effective concentration required to reduce CMV AD169 strain virus plaque formation by 50% in HEL cell culture	[PMID: 15481985]
HEL	EC₅₀	>400 μM Compound: brivudin	Effective concentration required to reduce CMV davis strain virus plaque formation by 50% in HEL cell culture Effective concentration required to reduce CMV davis strain virus plaque formation by 50% in HEL cell culture	[PMID: 15481985]
HEL	EC₅₀	0.003 μM Compound: brivudin	Effective concentration required to reduce TK+ (thymidine kinase presence) VZV strain OKA virus plaque formation by 50% in HEL cell culture Effective concentration required to reduce TK+ (thymidine kinase presence) VZV strain OKA virus plaque formation by 50% in HEL cell culture	[PMID: 15481985]
HEL	EC₅₀	0.003 μM Compound: brivudin	Effective concentration required to reduce TK+ (thymidine kinase presence) VZV strain YS virus plaque formation by 50% in HEL cell culture Effective concentration required to reduce TK+ (thymidine kinase presence) VZV strain YS virus plaque formation by 50% in HEL cell culture	[PMID: 15481985]
HEL	EC₅₀	29 μM Compound: brivudin	Effective concentration required to reduce TK+ (thymidine kinase deficient) VZV strain 07/1 virus plaque formation by 50% in HEL cell culture Effective concentration required to reduce TK+ (thymidine kinase deficient) VZV strain 07/1 virus plaque formation by 50% in HEL cell culture	[PMID: 15481985]
HEL	EC₅₀	56 μM Compound: brivudin	Effective concentration required to reduce TK+ (thymidine kinase deficient) VZV strain YS/R virus plaque formation by 50% in HEL cell culture Effective concentration required to reduce TK+ (thymidine kinase deficient) VZV strain YS/R virus plaque formation by 50% in HEL cell culture	[PMID: 15481985]
HEL	CC₅₀	249 μM Compound: Brivudin	Cytotoxic concentration required to reduce HEL cell growth Cytotoxic concentration required to reduce HEL cell growth	[PMID: 15801851]
HEL	EC₅₀	>100 μM Compound: Brivudin	Effective concentration required to inhibit human cytomegalo virus AD-169 induced cytopathicity in HEL fibroblast cell line after 7 days of postinfection Effective concentration required to inhibit human cytomegalo virus AD-169 induced cytopathicity in HEL fibroblast cell line after 7 days of postinfection	[PMID: 15801851]
HEL	EC₅₀	>100 μM Compound: Brivudin	Effective concentration required to inhibit human cytomegalo virus Davis induced cytopathicity in HEL fibroblast cell line after 7 days of postinfection Effective concentration required to inhibit human cytomegalo virus Davis induced cytopathicity in HEL fibroblast cell line after 7 days of postinfection	[PMID: 15801851]
HEL	EC₅₀	0.03 μM Compound: Brivudin	Effective concentration required to reduce Varicella-Zoster virus OKA(TK) plaque formation after 5 days in HEL fibroblast cell line Effective concentration required to reduce Varicella-Zoster virus OKA(TK) plaque formation after 5 days in HEL fibroblast cell line	[PMID: 15801851]
HEL	EC₅₀	103 μM Compound: Brivudin	Effective concentration required to reduce Varicella-Zoster virus 07/1(TK-) plaque formation after 5 days in HEL fibroblast cell line Effective concentration required to reduce Varicella-Zoster virus 07/1(TK-) plaque formation after 5 days in HEL fibroblast cell line	[PMID: 15801851]
HEL	EC₅₀	>100 μM Compound: BVDU	Concentration required to inhibit human cytomegalovirus strain AD169 induced cytopathogenicity in HEL cells by 50% Concentration required to inhibit human cytomegalovirus strain AD169 induced cytopathogenicity in HEL cells by 50%	[PMID: 16000005]
HEL	EC₅₀	>100 μM Compound: BVDU	Concentration required to inhibit human cytomegalovirus strain Davis induced cytopathogenicity in HEL cells by 50% Concentration required to inhibit human cytomegalovirus strain Davis induced cytopathogenicity in HEL cells by 50%	[PMID: 16000005]
HEL	EC₅₀	>108 μM Compound: BVDU	Concentration required to inhibit Varicella-Zoster virus (strain 07/1) induced cytopathogenicity in HEL cells by 50% Concentration required to inhibit Varicella-Zoster virus (strain 07/1) induced cytopathogenicity in HEL cells by 50%	[PMID: 16000005]
HEL	EC₅₀	>500 μM Compound: BVDU	Concentration required to inhibit vesicular stomatitis virus induced cytopathogenicity in HEL cells by 50% Concentration required to inhibit vesicular stomatitis virus induced cytopathogenicity in HEL cells by 50%	[PMID: 16000005]
HEL	EC₅₀	0.03 μM Compound: BVDU	Concentration required to inhibit Varicella-Zoster virus (strain OKA) induced cytopathogenicity in HEL cells by 50% Concentration required to inhibit Varicella-Zoster virus (strain OKA) induced cytopathogenicity in HEL cells by 50%	[PMID: 16000005]
HEL	EC₅₀	0.16 μM Compound: BVDU	Concentration required to inhibit herpes simplex virus type 1 induced cytopathogenicity in HEL cells by 50% Concentration required to inhibit herpes simplex virus type 1 induced cytopathogenicity in HEL cells by 50%	[PMID: 16000005]
HEL	EC₅₀	300 μM Compound: BVDU	Concentration required to inhibit herpes simplex virus type 2 induced cytopathogenicity in HEL cells by 50% Concentration required to inhibit herpes simplex virus type 2 induced cytopathogenicity in HEL cells by 50%	[PMID: 16000005]
HEL	EC₅₀	60 μM Compound: BVDU	Concentration required to inhibit vaccinia virus induced cytopathogenicity in HEL cells by 50% Concentration required to inhibit vaccinia virus induced cytopathogenicity in HEL cells by 50%	[PMID: 16000005]
HEL	CC₅₀	≥400 μM Compound: BVDU	Concentration required to inhibit cell proliferation in HEL cells by 50% Concentration required to inhibit cell proliferation in HEL cells by 50%	[PMID: 16000005]
HEL	CC₅₀	>150 μM Compound: BVDU	Cytotoxic activity against cultured human embryonic lung (HEL) cells Cytotoxic activity against cultured human embryonic lung (HEL) cells	[PMID: 16392824]
HEL	CC₅₀	>200 μg/mL Compound: Brivudin	Cytotoxicity against HEL cells Cytotoxicity against HEL cells	[PMID: 16480257]
HEL	CC₅₀	>500 μM Compound: Brivudin	Cytotoxicity against HEL cells Cytotoxicity against HEL cells	[PMID: 17181162]
HEL	EC₅₀	>500 μM Compound: Brivudin	Antiviral activity against vesicular somatitis virus in HEL cells Antiviral activity against vesicular somatitis virus in HEL cells	[PMID: 17181162]
HEL	EC₅₀	2.4 μM Compound: Brivudin	Antiviral activity against vaccinia virus in HEL cells Antiviral activity against vaccinia virus in HEL cells	[PMID: 17181162]
HEL	EC₅₀	300 μM Compound: Brivudin	Antiviral activity against HSV2 in HEL cells Antiviral activity against HSV2 in HEL cells	[PMID: 17181162]
HEL	EC₅₀	>20 μg/mL Compound: brivudin	Antiviral activity against ACV-resistant TK- HSV1 KOS in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against ACV-resistant TK- HSV1 KOS in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 17298047]
HEL	EC₅₀	>=122.1 μg/mL Compound: brivudin	Antiviral activity against TK- VZV 07-1 in HEL cells assessed as inhibition of plaque formation Antiviral activity against TK- VZV 07-1 in HEL cells assessed as inhibition of plaque formation	[PMID: 17298047]
HEL	EC₅₀	0.0025 μg/mL Compound: brivudin	Antiviral activity against HSV1 KOS in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against HSV1 KOS in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 17298047]
HEL	EC₅₀	0.0069 μg/mL Compound: brivudin	Antiviral activity against VZV OKA in HEL cells assessed as inhibition of plaque formation Antiviral activity against VZV OKA in HEL cells assessed as inhibition of plaque formation	[PMID: 17298047]
HEL	EC₅₀	8.8 μg/mL Compound: brivudin	Antiviral activity against HSV2 Lyons in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against HSV2 Lyons in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 17298047]
HEL	EC₅₀	8.97 μg/mL Compound: brivudin	Antiviral activity against HSV2 G in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against HSV2 G in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 17298047]
HEL	CC₅₀	408 μM Compound: brivudin	Cytotoxicity against HEL cells assessed as cell growth after 7 days Cytotoxicity against HEL cells assessed as cell growth after 7 days	[PMID: 17539622]
HEL	EC₅₀	0.02 μg/mL Compound: Brivudin	Antiviral activity against TK+ VZV OKA infected HEL cells assessed as reduction in virus plaque formation Antiviral activity against TK+ VZV OKA infected HEL cells assessed as reduction in virus plaque formation	[PMID: 17583388]
HEL	EC₅₀	25 μg/mL Compound: Brivudin	Antiviral activity against TK- VZV 07/1 infected HEL cells assessed as reduction in virus plaque formation Antiviral activity against TK- VZV 07/1 infected HEL cells assessed as reduction in virus plaque formation	[PMID: 17583388]
HEL	CC₅₀	>150 μM Compound: BVDU	Cytotoxicity against HEL cells after 3 days Cytotoxicity against HEL cells after 3 days	[PMID: 17622128]
HEL	EC₅₀	0.01 μM Compound: BVDU	Antiviral activity against TK+ VZV OKA in HEL cells assessed as reduction of virus plaque formation after 5 days Antiviral activity against TK+ VZV OKA in HEL cells assessed as reduction of virus plaque formation after 5 days	[PMID: 17622128]
HEL	EC₅₀	0.01 μM Compound: BVDU	Antiviral activity against TK+ VZV YS in HEL cells assessed as reduction of virus plaque formation after 5 days Antiviral activity against TK+ VZV YS in HEL cells assessed as reduction of virus plaque formation after 5 days	[PMID: 17622128]
HEL	EC₅₀	≥130 μM Compound: BVDU	Antiviral activity against thymidine kinase deficient VZV YS/R in HEL cells assessed as reduction of virus plaque formation after 5 days Antiviral activity against thymidine kinase deficient VZV YS/R in HEL cells assessed as reduction of virus plaque formation after 5 days	[PMID: 17622128]
HEL	EC₅₀	≥99 μM Compound: BVDU	Antiviral activity against thymidine kinase deficient VZV 07/1 in HEL cells assessed as reduction of virus plaque formation after 5 days Antiviral activity against thymidine kinase deficient VZV 07/1 in HEL cells assessed as reduction of virus plaque formation after 5 days	[PMID: 17622128]
HEL	CC₅₀	270 μM Compound: brivudin	Cytotoxicity against human HEL cells assessed as reduction of cell growth Cytotoxicity against human HEL cells assessed as reduction of cell growth	[PMID: 17672445]
HEL	EC₅₀	0.014 μM Compound: brivudin	Antiviral activity against thymidine kinase-positive VZV OKA in human HEL cells after 7 days Antiviral activity against thymidine kinase-positive VZV OKA in human HEL cells after 7 days	[PMID: 17672445]
HEL	EC₅₀	168 μM Compound: brivudin	Antiviral activity against thymidine kinase deficient VZV 07/1 in human HEL cells after 7 days Antiviral activity against thymidine kinase deficient VZV 07/1 in human HEL cells after 7 days	[PMID: 17672445]
HEL	EC₅₀	0.0038 μg/mL Compound: brivudin	Antiviral activity against TK+ VZV OKA in HEL cells assessed as reduction of virus plaque formation Antiviral activity against TK+ VZV OKA in HEL cells assessed as reduction of virus plaque formation	[PMID: 17869124]
HEL	EC₅₀	362 μg/mL Compound: brivudin	Antiviral activity against TK- VZV 07/1 in HEL cells assessed as reduction of virus plaque formation Antiviral activity against TK- VZV 07/1 in HEL cells assessed as reduction of virus plaque formation	[PMID: 17869124]
HEL	CC₅₀	212 μg/mL Compound: brivudin	Cytotoxicity against HEL cells assessed as cell growth after 3 days Cytotoxicity against HEL cells assessed as cell growth after 3 days	[PMID: 17948980]
HEL	EC₅₀	>20 μg/mL Compound: brivudin	Antiviral activity against acyclovir-resistant HSV1 KOS TK- in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against acyclovir-resistant HSV1 KOS TK- in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17948980]
HEL	EC₅₀	>=44.4 μg/mL Compound: brivudin	Antiviral activity against VZV 07-1 TK- in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against VZV 07-1 TK- in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17948980]
HEL	EC₅₀	0.0022 μg/mL Compound: brivudin	Antiviral activity against VZV OKA in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against VZV OKA in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17948980]
HEL	EC₅₀	0.0024 μg/mL Compound: brivudin	Antiviral activity against HSV1 KOS in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against HSV1 KOS in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17948980]
HEL	EC₅₀	200 μg/mL Compound: brivudin	Antiviral activity against VSV in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against VSV in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17948980]
HEL	EC₅₀	8.8 μg/mL Compound: brivudin	Antiviral activity against HSV2 Lyons in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against HSV2 Lyons in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17948980]
HEL	EC₅₀	9 μg/mL Compound: brivudin	Antiviral activity against HSV2 G in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against HSV2 G in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17948980]
HEL	CC₅₀	>200 μM Compound: 13, BVdU	Cytotoxicity against HEL cells Cytotoxicity against HEL cells	[PMID: 18052321]
HEL	EC₅₀	>200 μM Compound: 13, BVdU	Antiviral activity against TK- VZV 07 in HEL cells after 5 days Antiviral activity against TK- VZV 07 in HEL cells after 5 days	[PMID: 18052321]
HEL	EC₅₀	>200 μM Compound: 13, BVdU	Antiviral activity against TK- VZV YS in HEL cells after 5 days Antiviral activity against TK- VZV YS in HEL cells after 5 days	[PMID: 18052321]
HEL	EC₅₀	0.005 μM Compound: 13, BVdU	Antiviral activity against TK+ VZV OKA in HEL cells after 5 days Antiviral activity against TK+ VZV OKA in HEL cells after 5 days	[PMID: 18052321]
HEL	EC₅₀	0.005 μM Compound: 13, BVdU	Antiviral activity against TK+ VZV YS in HEL cells after 5 days Antiviral activity against TK+ VZV YS in HEL cells after 5 days	[PMID: 18052321]
HEL	CC₅₀	122 μg/mL Compound: brivudin	Cytotoxicity against HEL cells assessed as reduction of growth after 3 days Cytotoxicity against HEL cells assessed as reduction of growth after 3 days	[PMID: 18835175]
HEL	EC₅₀	0.0037 μg/mL Compound: brivudin	Antiviral activity against thymidine kinase expressing Varicella-Zoster virus Oka in HEL cells assessed as inhibition of viral cytopathicity Antiviral activity against thymidine kinase expressing Varicella-Zoster virus Oka in HEL cells assessed as inhibition of viral cytopathicity	[PMID: 18835175]
HEL	EC₅₀	50 μg/mL Compound: brivudin	Antiviral activity against thymidine kinase deficient Varicella-Zoster virus 07/1 in HEL cells assessed as inhibition of viral cytopathicity Antiviral activity against thymidine kinase deficient Varicella-Zoster virus 07/1 in HEL cells assessed as inhibition of viral cytopathicity	[PMID: 18835175]
HEL	EC₅₀	>250 μg/mL Compound: brivudin	Antiviral activity against VSV infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days Antiviral activity against VSV infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days	[PMID: 18851889]
HEL	EC₅₀	0.04 μg/mL Compound: brivudin	Antiviral activity against HSV1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days Antiviral activity against HSV1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days	[PMID: 18851889]
HEL	EC₅₀	29 μg/mL Compound: brivudin	Antiviral activity against HSV2 G infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days Antiviral activity against HSV2 G infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days	[PMID: 18851889]
HEL	EC₅₀	5 μg/mL Compound: brivudin	Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days	[PMID: 18851889]
HEL	EC₅₀	96 μg/mL Compound: brivudin	Antiviral activity against thymidine kinase-deficient acyclovir-resistant HSV1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days Antiviral activity against thymidine kinase-deficient acyclovir-resistant HSV1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days	[PMID: 18851889]
HEL	CC₅₀	600 μM Compound: brivudin	Cytotoxicity against human HEL cells assessed as reduction of growth after 3 days Cytotoxicity against human HEL cells assessed as reduction of growth after 3 days	[PMID: 19226140]
HEL	EC₅₀	0.015 μM Compound: brivudin	Antiviral activity against thymidine kinase expressing Varicella zoster virus Oka infected in human HEL cells assessed reduction in viral plaque formation Antiviral activity against thymidine kinase expressing Varicella zoster virus Oka infected in human HEL cells assessed reduction in viral plaque formation	[PMID: 19226140]
HEL	EC₅₀	140 μM Compound: brivudin	Antiviral activity against thymidine kinase deficient Varicella zoster virus 07/1 infected in human HEL cells assessed reduction in viral plaque formation Antiviral activity against thymidine kinase deficient Varicella zoster virus 07/1 infected in human HEL cells assessed reduction in viral plaque formation	[PMID: 19226140]
HEL	EC₅₀	>250 μM Compound: BRV	Antiviral activity against VSV in human HEL cells assessed as protection against virus-induced cytopathicity Antiviral activity against VSV in human HEL cells assessed as protection against virus-induced cytopathicity	[PMID: 19281225]
HEL	EC₅₀	0.02 μM Compound: BRV	Antiviral activity against HSV1 KOS in human HEL cells assessed as protection against virus-induced cytopathicity Antiviral activity against HSV1 KOS in human HEL cells assessed as protection against virus-induced cytopathicity	[PMID: 19281225]
HEL	EC₅₀	29 μM Compound: BRV	Antiviral activity against HSV2 G in human HEL cells assessed as protection against virus-induced cytopathicity Antiviral activity against HSV2 G in human HEL cells assessed as protection against virus-induced cytopathicity	[PMID: 19281225]
HEL	EC₅₀	4 μM Compound: BRV	Antiviral activity against Vaccinia virus Lederle in human HEL cells assessed as protection against virus-induced cytopathicity Antiviral activity against Vaccinia virus Lederle in human HEL cells assessed as protection against virus-induced cytopathicity	[PMID: 19281225]
HEL	EC₅₀	50 μM Compound: BRV	Antiviral activity against thymidine kinase deficient and acyclovir resistant HSV1 KOS in human HEL cells assessed as protection against virus-induced cytopathicity Antiviral activity against thymidine kinase deficient and acyclovir resistant HSV1 KOS in human HEL cells assessed as protection against virus-induced cytopathicity	[PMID: 19281225]
HEL	CC₅₀	432 μM Compound: brivudin	Cytotoxicity against human HEL cells assessed as reduction in cell growth after 3 days Cytotoxicity against human HEL cells assessed as reduction in cell growth after 3 days	[PMID: 19339082]
HEL	EC₅₀	0.015 μM Compound: brivudin	Antiviral activity against Varicella zoster virus OKA infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 5 days Antiviral activity against Varicella zoster virus OKA infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 5 days	[PMID: 19339082]
HEL	EC₅₀	0.026 μM Compound: brivudin	Antiviral activity against Varicella zoster virus YS infected in human HEL cells assessed as inhibition of virus induced cytopathicity after 5 days Antiviral activity against Varicella zoster virus YS infected in human HEL cells assessed as inhibition of virus induced cytopathicity after 5 days	[PMID: 19339082]
HEL	EC₅₀	157 μM Compound: brivudin	Antiviral activity against thymidine kinase deficient Varicella zoster virus 07/1 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 5 days Antiviral activity against thymidine kinase deficient Varicella zoster virus 07/1 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 5 days	[PMID: 19339082]
HEL	EC₅₀	>250 μg/mL Compound: brivudin	Antiviral activity against thymidine kinase-deficient ACV-resistant HSV1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days Antiviral activity against thymidine kinase-deficient ACV-resistant HSV1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days	[PMID: 19419804]
HEL	EC₅₀	>250 μg/mL Compound: brivudin	Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days	[PMID: 19419804]
HEL	EC₅₀	0.08 μg/mL Compound: brivudin	Antiviral activity against HSV1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days Antiviral activity against HSV1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days	[PMID: 19419804]
HEL	EC₅₀	10 μg/mL Compound: brivudin	Antiviral activity against Vaccinia virus infected in in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days Antiviral activity against Vaccinia virus infected in in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days	[PMID: 19419804]
HEL	EC₅₀	126 μg/mL Compound: brivudin	Antiviral activity against HSV2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days Antiviral activity against HSV2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days	[PMID: 19419804]
HEL	CC₅₀	>250 μM Compound: Brivudine	Cytotoxicity against acyclovir-sensitive Herpes simplex virus 1 KOS infected HEL cells by trypan blue exclusion method Cytotoxicity against acyclovir-sensitive Herpes simplex virus 1 KOS infected HEL cells by trypan blue exclusion method	[PMID: 20034711]
HEL	CC₅₀	>250 μM Compound: Brivudine	Cytotoxicity against Herpes simplex virus 1 KOS infected HEL cells by trypan blue exclusion method Cytotoxicity against Herpes simplex virus 1 KOS infected HEL cells by trypan blue exclusion method	[PMID: 20034711]
HEL	CC₅₀	>250 μM Compound: Brivudine	Cytotoxicity against Herpes simplex virus 2 G infected HEL cells by trypan blue exclusion method Cytotoxicity against Herpes simplex virus 2 G infected HEL cells by trypan blue exclusion method	[PMID: 20034711]
HEL	CC₅₀	>250 μM Compound: Brivudine	Cytotoxicity against Vaccinia virus infected HEL cells by trypan blue exclusion method Cytotoxicity against Vaccinia virus infected HEL cells by trypan blue exclusion method	[PMID: 20034711]
HEL	CC₅₀	>250 μM Compound: Brivudine	Cytotoxicity against VSV infected HEL cells by trypan blue exclusion method Cytotoxicity against VSV infected HEL cells by trypan blue exclusion method	[PMID: 20034711]
HEL	EC₅₀	>250 μM Compound: Brivudine	Antiviral activity against VSV infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 1 to 2 days by MTT assay Antiviral activity against VSV infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 1 to 2 days by MTT assay	[PMID: 20034711]
HEL	EC₅₀	0.08 μM Compound: Brivudine	Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay	[PMID: 20034711]
HEL	EC₅₀	2 μM Compound: Brivudine	Antiviral activity against Vaccinia virus infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay Antiviral activity against Vaccinia virus infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay	[PMID: 20034711]
HEL	EC₅₀	50 μM Compound: Brivudine	Antiviral activity against acyclovir-sensitive Herpes simplex virus 1 KOS infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay Antiviral activity against acyclovir-sensitive Herpes simplex virus 1 KOS infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay	[PMID: 20034711]
HEL	EC₅₀	50 μM Compound: Brivudine	Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay	[PMID: 20034711]
HEL	EC₅₀	>250 μg/mL Compound: Brivudine	Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days	[PMID: 20724039]
HEL	EC₅₀	0.04 μg/mL Compound: Brivudine	Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days	[PMID: 20724039]
HEL	EC₅₀	250 μg/mL Compound: Brivudine	Antiviral activity against acyclovir-resistant TK deficient Herpes simplex virus-1 KOS infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days Antiviral activity against acyclovir-resistant TK deficient Herpes simplex virus-1 KOS infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days	[PMID: 20724039]
HEL	EC₅₀	4 μg/mL Compound: Brivudine	Antiviral activity against Vaccinia virus infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days Antiviral activity against Vaccinia virus infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days	[PMID: 20724039]
HEL	EC₅₀	50 μg/mL Compound: Brivudine	Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days	[PMID: 20724039]
HEL	CC₅₀	>300 μM Compound: Brivurdin	Cytotoxicity against HEL assessed as change in cell morphology Cytotoxicity against HEL assessed as change in cell morphology	[PMID: 20809641]
HEL	CC₅₀	339 μM Compound: Brivurdin	Cytotoxicity against HEL Cytotoxicity against HEL	[PMID: 20809641]
HEL	EC₅₀	>250 μg/mL Compound: Brivudin	Antiviral activity against thymidine kinase deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay Antiviral activity against thymidine kinase deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay	[PMID: 20971531]
HEL	EC₅₀	>250 μg/mL Compound: Brivudin	Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay	[PMID: 20971531]
HEL	EC₅₀	0.08 μg/mL Compound: Brivudin	Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay	[PMID: 20971531]
HEL	EC₅₀	112 μg/mL Compound: Brivudin	Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay	[PMID: 20971531]
HEL	EC₅₀	250 μg/mL Compound: Brivudin	Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay	[PMID: 20971531]
HEL	CC₅₀	>250 μM Compound: Brivudin	Cytotoxicity against human HEL cells after 3 days Cytotoxicity against human HEL cells after 3 days	[PMID: 21128666]
HEL	EC₅₀	>100 μM Compound: Brivudin	Antiviral activity against thymidine kinase-deficient VZV 07/1 infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 5 days Antiviral activity against thymidine kinase-deficient VZV 07/1 infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 5 days	[PMID: 21128666]
HEL	EC₅₀	>250 μM Compound: Brivudin	Antiviral activity against HCMV AD169/Davis infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days Antiviral activity against HCMV AD169/Davis infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days	[PMID: 21128666]
HEL	EC₅₀	0.012 μM Compound: Brivudin	Antiviral activity against VZV OKA expressing thymidine kinase infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 5 days Antiviral activity against VZV OKA expressing thymidine kinase infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 5 days	[PMID: 21128666]
HEL	EC₅₀	0.04 μM Compound: Brivudin	Antiviral activity against HSV1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days Antiviral activity against HSV1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days	[PMID: 21128666]
HEL	EC₅₀	1.5 μM Compound: Brivudin	Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days	[PMID: 21128666]
HEL	EC₅₀	250 μM Compound: Brivudin	Antiviral activity against acyclovir-resistant thymidine kinase deficient HSV1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days Antiviral activity against acyclovir-resistant thymidine kinase deficient HSV1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days	[PMID: 21128666]
HEL	EC₅₀	30 μM Compound: Brivudin	Antiviral activity against HSV2 G infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days Antiviral activity against HSV2 G infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days	[PMID: 21128666]
HEL	CC₅₀	>250 μM Compound: BVDU	Cytotoxicity against HEL cells after 3 days by coulter counter analysis Cytotoxicity against HEL cells after 3 days by coulter counter analysis	[PMID: 21232828]
HEL	EC₅₀	0.003 μM Compound: BVDU	Antiviral activity against VZV OKA expressing thymidine kinase infected in HEL cells assessed as inhibition of plaque formation Antiviral activity against VZV OKA expressing thymidine kinase infected in HEL cells assessed as inhibition of plaque formation	[PMID: 21232828]
HEL	EC₅₀	0.02 μM Compound: BVDU	Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 21232828]
HEL	EC₅₀	180 μM Compound: BVDU	Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 21232828]
HEL	EC₅₀	2 μM Compound: BVDU	Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 21232828]
HEL	EC₅₀	54.4 μM Compound: BVDU	Antiviral activity against VZV 07-1 infected in HEL cells assessed as inhibition of plaque formation Antiviral activity against VZV 07-1 infected in HEL cells assessed as inhibition of plaque formation	[PMID: 21232828]
HEL	EC₅₀	6 μM Compound: BVDU	Antiviral activity against thymidine kinase deficient acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against thymidine kinase deficient acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 21232828]
HEL	CC₅₀	470 μM Compound: Brivudin	Cytotoxicity against human HEL cells assessed as growth inhibition after 3 days by coulter counter Cytotoxicity against human HEL cells assessed as growth inhibition after 3 days by coulter counter	[PMID: 21565516]
HEL	EC₅₀	>=105.4 μM Compound: Brivudin	Antiviral activity against VZV 07/1 infected in HEL cells assessed as protection against virus-induced cytopathicity Antiviral activity against VZV 07/1 infected in HEL cells assessed as protection against virus-induced cytopathicity	[PMID: 21565516]
HEL	EC₅₀	0.013 μM Compound: Brivudin	Antiviral activity against VZV OKA infected in HEL cells assessed as protection against virus-induced cytopathicity Antiviral activity against VZV OKA infected in HEL cells assessed as protection against virus-induced cytopathicity	[PMID: 21565516]
HEL	EC₅₀	0.028 μM Compound: Brivudin	Antiviral activity against Human herpesvirus 1 KOS infected in HEL cells assessed as protection against virus-induced cytopathicity Antiviral activity against Human herpesvirus 1 KOS infected in HEL cells assessed as protection against virus-induced cytopathicity	[PMID: 21565516]
HEL	EC₅₀	274.3 μM Compound: Brivudin	Antiviral activity against acyclovir-resistant Human herpesvirus 1 KOS infected in HEL cells assessed as protection against virus-induced cytopathicity Antiviral activity against acyclovir-resistant Human herpesvirus 1 KOS infected in HEL cells assessed as protection against virus-induced cytopathicity	[PMID: 21565516]
HEL	EC₅₀	4 μM Compound: Brivudin	Antiviral activity against Vaccinia virus infected in HEL cells assessed as protection against virus-induced cytopathicity Antiviral activity against Vaccinia virus infected in HEL cells assessed as protection against virus-induced cytopathicity	[PMID: 21565516]
HEL	EC₅₀	45.7 μM Compound: Brivudin	Antiviral activity against Human herpesvirus 2 G infected in HEL cells assessed as protection against virus-induced cytopathicity Antiviral activity against Human herpesvirus 2 G infected in HEL cells assessed as protection against virus-induced cytopathicity	[PMID: 21565516]
HEL	CC₅₀	512 μM Compound: Brivudin	Cytotoxicity against human HEL cells by colorimetric formazan-based MTS assay Cytotoxicity against human HEL cells by colorimetric formazan-based MTS assay	[PMID: 21696963]
HEL	EC₅₀	>150 μM Compound: Brivudin	Antiviral activity against thymidine kinase-deficient Varicella-zoster virus YS/R infected in human HEL cells assessed as reduction in the virus plaque formation Antiviral activity against thymidine kinase-deficient Varicella-zoster virus YS/R infected in human HEL cells assessed as reduction in the virus plaque formation	[PMID: 21696963]
HEL	EC₅₀	>=60 μM Compound: Brivudin	Antiviral activity against thymidine kinase-deficient Varicella-zoster virus 07-1 infected in human HEL cells assessed as reduction in the virus plaque formation Antiviral activity against thymidine kinase-deficient Varicella-zoster virus 07-1 infected in human HEL cells assessed as reduction in the virus plaque formation	[PMID: 21696963]
HEL	EC₅₀	0.011 μM Compound: Brivudin	Antiviral activity against Varicella-zoster virus YS expressing thymidine kinase infected in human HEL cells assessed as reduction in the virus plaque formation Antiviral activity against Varicella-zoster virus YS expressing thymidine kinase infected in human HEL cells assessed as reduction in the virus plaque formation	[PMID: 21696963]
HEL	EC₅₀	0.03 μM Compound: Brivudin	Antiviral activity against Varicella-zoster virus OKA expressing thymidine kinase infected in human HEL cells assessed as reduction in the virus plaque formation Antiviral activity against Varicella-zoster virus OKA expressing thymidine kinase infected in human HEL cells assessed as reduction in the virus plaque formation	[PMID: 21696963]
HEL	EC₅₀	0.08 μM Compound: Brivudin	Antiviral activity against Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis Antiviral activity against Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis	[PMID: 21696963]
HEL	EC₅₀	10 μM Compound: Brivudin	Antiviral activity against Vaccinia virus infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis Antiviral activity against Vaccinia virus infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis	[PMID: 21696963]
HEL	EC₅₀	250 μM Compound: Brivudin	Antiviral activity against acyclovir-resistant TK-deficient Herpes simplex virus-1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis Antiviral activity against acyclovir-resistant TK-deficient Herpes simplex virus-1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis	[PMID: 21696963]
HEL	EC₅₀	250 μM Compound: Brivudin	Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis	[PMID: 21696963]
HEL	EC₅₀	>250 μM Compound: Brivudin	Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days	[PMID: 22459876]
HEL	EC₅₀	0.01 μM Compound: Brivudin	Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days	[PMID: 22459876]
HEL	EC₅₀	0.019 μM Compound: Brivudin	Antiviral activity against VSV OKA expressing thymidine kinase infected in HEL cells assessed as reduction of virus plaque formation after 4 days Antiviral activity against VSV OKA expressing thymidine kinase infected in HEL cells assessed as reduction of virus plaque formation after 4 days	[PMID: 22459876]
HEL	EC₅₀	10 μM Compound: Brivudin	Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days	[PMID: 22459876]
HEL	EC₅₀	250 μM Compound: Brivudin	Antiviral activity against thymidine kinase-deficient acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days Antiviral activity against thymidine kinase-deficient acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days	[PMID: 22459876]
HEL	EC₅₀	50 μM Compound: Brivudin	Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days	[PMID: 22459876]
HEL	CC₅₀	>100 μM Compound: BVDU	Cytostatic against human HEL cells assessed as reduction in cell growth after 3 days by coulter counter Cytostatic against human HEL cells assessed as reduction in cell growth after 3 days by coulter counter	[PMID: 22578783]
HEL	EC₅₀	0.0075 μM Compound: BVDU	Antiviral activity against thymidine kinase-positive Varicella-zoster virus YS infected in HEL cells assessed as reduction in virus-induced cytopathicity Antiviral activity against thymidine kinase-positive Varicella-zoster virus YS infected in HEL cells assessed as reduction in virus-induced cytopathicity	[PMID: 22578783]
HEL	EC₅₀	0.0087 μM Compound: BVDU	Antiviral activity against thymidine kinase-positive Varicella-zoster virus OKA infected in HEL cells assessed as reduction in virus-induced cytopathicity Antiviral activity against thymidine kinase-positive Varicella-zoster virus OKA infected in HEL cells assessed as reduction in virus-induced cytopathicity	[PMID: 22578783]
HEL	EC₅₀	74 μM Compound: BVDU	Antiviral activity against thymidine kinase-deficient Varicella-zoster virus 07/1 infected in HEL cells assessed as reduction in virus-induced cytopathicity Antiviral activity against thymidine kinase-deficient Varicella-zoster virus 07/1 infected in HEL cells assessed as reduction in virus-induced cytopathicity	[PMID: 22578783]
HEL	CC₅₀	347 μM Compound: Brivudin	Cytotoxicity against HEL cells assessed as effect on cell growth incubated for 3 days by Coulter counter assay Cytotoxicity against HEL cells assessed as effect on cell growth incubated for 3 days by Coulter counter assay	[PMID: 22858222]
HEL	EC₅₀	0.006 μM Compound: Brivudin	Antiviral activity against thymidine kinase positive VZV YS infected in HEL cells by plaque formation assay Antiviral activity against thymidine kinase positive VZV YS infected in HEL cells by plaque formation assay	[PMID: 22858222]
HEL	EC₅₀	0.01 μM Compound: Brivudin	Antiviral activity against thymidine kinase positive VZV OKa infected in HEL cells by plaque formation assay Antiviral activity against thymidine kinase positive VZV OKa infected in HEL cells by plaque formation assay	[PMID: 22858222]
HEL	EC₅₀	0.038 μM Compound: Brivudin	Antiviral activity against HSV1 KOS infected in HEL cells by viral CPE assay Antiviral activity against HSV1 KOS infected in HEL cells by viral CPE assay	[PMID: 22858222]
HEL	EC₅₀	105 μM Compound: Brivudin	Antiviral activity against HSV2 G infected in HEL cells by viral CPE assay Antiviral activity against HSV2 G infected in HEL cells by viral CPE assay	[PMID: 22858222]
HEL	EC₅₀	15 μM Compound: Brivudin	Antiviral activity against Vaccinia virus Lederie infected in HEL cells by viral CPE assay Antiviral activity against Vaccinia virus Lederie infected in HEL cells by viral CPE assay	[PMID: 22858222]
HEL	EC₅₀	53 μM Compound: Brivudin	Antiviral activity against thymidine kinase negative VZV 07/01 infected in HEL cells by plaque formation assay Antiviral activity against thymidine kinase negative VZV 07/01 infected in HEL cells by plaque formation assay	[PMID: 22858222]
HEL	EC₅₀	≥120 μM Compound: Brivudin	Antiviral activity against thymidine kinase negative VZV YS/R infected in HEL cells by plaque formation assay Antiviral activity against thymidine kinase negative VZV YS/R infected in HEL cells by plaque formation assay	[PMID: 22858222]
HEL	EC₅₀	≥183 μM Compound: Brivudin	Antiviral activity against thymidine kinase negative and ACV resistant HSV1 KOS infected in HEL cells by viral CPE assay Antiviral activity against thymidine kinase negative and ACV resistant HSV1 KOS infected in HEL cells by viral CPE assay	[PMID: 22858222]
HEL	CC₅₀	339 μM Compound: Brivudine	Cytotoxicity against HEL after 3 days Cytotoxicity against HEL after 3 days	[PMID: 23047229]
HEL	EC₅₀	0.01 μM Compound: Brivudine	Antiviral activity against VZV OKA expressing thymidine kinase infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 3 days Antiviral activity against VZV OKA expressing thymidine kinase infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 3 days	[PMID: 23047229]
HEL	EC₅₀	117 μM Compound: Brivudine	Antiviral activity against thymidine kinase-deficient VZV 07/1 infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 3 days Antiviral activity against thymidine kinase-deficient VZV 07/1 infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 3 days	[PMID: 23047229]
HEL	EC₅₀	>250 μM Compound: Brivudin	Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 23099097]
HEL	EC₅₀	0.024 μM Compound: Brivudin	Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 23099097]
HEL	EC₅₀	10 μM Compound: Brivudin	Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 23099097]
HEL	EC₅₀	198 μM Compound: Brivudin	Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 23099097]
HEL	EC₅₀	50 μM Compound: Brivudin	Antiviral activity against thymidine kinase deficient and acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against thymidine kinase deficient and acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 23099097]
HEL	EC₅₀	>250 μM Compound: brivudin	Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 23811093]
HEL	EC₅₀	0.04 μM Compound: brivudin	Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 23811093]
HEL	EC₅₀	144.9 μM Compound: brivudin	Antiviral activity against TK-positive Varicella-zoster virus 07-1 infected in human HEL cells assessed as reduction of plaque formation Antiviral activity against TK-positive Varicella-zoster virus 07-1 infected in human HEL cells assessed as reduction of plaque formation	[PMID: 23811093]
HEL	EC₅₀	146 μM Compound: brivudin	Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 23811093]
HEL	EC₅₀	250 μM Compound: brivudin	Antiviral activity against TK-negative Herpes simplex virus 1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against TK-negative Herpes simplex virus 1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 23811093]
HEL	EC₅₀	3.82 μM Compound: brivudin	Antiviral activity against TK-positive Varicella-zoster virus OKA infected in human HEL cells assessed as reduction of plaque formation Antiviral activity against TK-positive Varicella-zoster virus OKA infected in human HEL cells assessed as reduction of plaque formation	[PMID: 23811093]
HEL	EC₅₀	5 μM Compound: brivudin	Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 23811093]
HEL	EC₅₀	>250 μM Compound: Brivudin	Antiviral activity against thymidine kinase negative acyclovir positive Herpes simplex virus-1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity Antiviral activity against thymidine kinase negative acyclovir positive Herpes simplex virus-1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity	[PMID: 23911856]
HEL	EC₅₀	>250 μM Compound: Brivudin	Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity	[PMID: 23911856]
HEL	EC₅₀	0.02 μM Compound: Brivudin	Antiviral activity against thymidine kinase positive Varicella-zoster virus OKA infected in human HEL cells assessed as reduction in virus plaque formation Antiviral activity against thymidine kinase positive Varicella-zoster virus OKA infected in human HEL cells assessed as reduction in virus plaque formation	[PMID: 23911856]
HEL	EC₅₀	0.4 μM Compound: Brivudin	Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity	[PMID: 23911856]
HEL	EC₅₀	10 μM Compound: Brivudin	Antiviral activity against Vaccinia virus Lederle infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity Antiviral activity against Vaccinia virus Lederle infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity	[PMID: 23911856]
HEL	EC₅₀	250 μM Compound: Brivudin	Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity	[PMID: 23911856]
HEL	EC₅₀	33 μM Compound: Brivudin	Antiviral activity against thymidine kinase negative Varicella-zoster virus 07-1 infected in human HEL cells assessed as reduction in the virus plaque formation Antiviral activity against thymidine kinase negative Varicella-zoster virus 07-1 infected in human HEL cells assessed as reduction in the virus plaque formation	[PMID: 23911856]
HEL	EC₅₀	0.01 μM Compound: Brivudin	Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 26001344]
HEL	EC₅₀	0.029 μM Compound: Brivudin	Antiviral activity against Varicella-zoster virus expressing thymidine kinase infected in HEL cells assessed as reduction of virus-induced plaque formation Antiviral activity against Varicella-zoster virus expressing thymidine kinase infected in HEL cells assessed as reduction of virus-induced plaque formation	[PMID: 26001344]
HEL	EC₅₀	1 μM Compound: Brivudin	Antiviral activity against thymidine kinase-deficient Varicella-zoster virus infected in HEL cells assessed as reduction of virus-induced plaque formation Antiviral activity against thymidine kinase-deficient Varicella-zoster virus infected in HEL cells assessed as reduction of virus-induced plaque formation	[PMID: 26001344]
HEL	EC₅₀	146 μM Compound: Brivudin	Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 26001344]
HEL	EC₅₀	17 μM Compound: Brivudin	Antiviral activity against Vaccinia virus infected in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against Vaccinia virus infected in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 26001344]
HEL	EC₅₀	2 μM Compound: Brivudin	Antiviral activity against thymidine kinase-deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against thymidine kinase-deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 26001344]
HEL	EC₅₀	0.029 μM Compound: Brivudin	Antiviral activity against thymidine kinase-deficient Varicella zoster virus Oka infected in HEL cells assessed as reduction in viral plaque formation Antiviral activity against thymidine kinase-deficient Varicella zoster virus Oka infected in HEL cells assessed as reduction in viral plaque formation	[PMID: 26443550]
HEL	EC₅₀	38.6 μM Compound: Brivudin	Antiviral activity against thymidine kinase-positive Varicella zoster virus 07-1 infected in HEL cells assessed as reduction in viral plaque formation Antiviral activity against thymidine kinase-positive Varicella zoster virus 07-1 infected in HEL cells assessed as reduction in viral plaque formation	[PMID: 26443550]
HEL	CC₅₀	≥79.3 μM Compound: Brivudin	Cytotoxicity against Varicella zoster virus infected HEL cells assessed as cell growth inhibition incubated for 3 days by coulter counter method Cytotoxicity against Varicella zoster virus infected HEL cells assessed as cell growth inhibition incubated for 3 days by coulter counter method	[PMID: 26443550]
HEL	CC₅₀	160 μM Compound: Brivudin	Cytotoxicity against HEL cells assessed as growth inhibition after 3 days by coulter counter method Cytotoxicity against HEL cells assessed as growth inhibition after 3 days by coulter counter method	[PMID: 27639368]
HEL	EC₅₀	0.007 μM Compound: Brivudin	Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus plaque formation Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus plaque formation	[PMID: 27639368]
HEL	EC₅₀	0.019 μM Compound: Brivudin	Antiviral activity against thymidine Kinase expressing Varicella-Zoster virus OKA infected in HEL cells assessed as inhibition of virus plaque formation Antiviral activity against thymidine Kinase expressing Varicella-Zoster virus OKA infected in HEL cells assessed as inhibition of virus plaque formation	[PMID: 27639368]
HEL	EC₅₀	33 μM Compound: Brivudin	Antiviral activity against thymidine kinase deficient Varicella-Zoster virus 07-1 infected in HEL cells assessed as inhibition of virus plaque formation Antiviral activity against thymidine kinase deficient Varicella-Zoster virus 07-1 infected in HEL cells assessed as inhibition of virus plaque formation	[PMID: 27639368]
HEL	EC₅₀	50 μM Compound: Brivudin	Antiviral activity against thymidine kinase-deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus plaque formation Antiviral activity against thymidine kinase-deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus plaque formation	[PMID: 27639368]
HEL	EC₅₀	96 μM Compound: Brivudin	Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus plaque formation Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus plaque formation	[PMID: 27639368]
HEL	EC₅₀	15 μM Compound: Brivudine	Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 27742238]
HEL	CC₅₀	300 μM Compound: Brivudin	Cytotoxicity against HEL cells infected with Varicella-Zoster virus assessed as growth inhibition Cytotoxicity against HEL cells infected with Varicella-Zoster virus assessed as growth inhibition	[PMID: 27750154]
HEL	CC₅₀	>300 μM Compound: Brivudine	Cytotoxic activity against HEL cells assessed as reduction in cell proliferation after 3 days by coulter counting method Cytotoxic activity against HEL cells assessed as reduction in cell proliferation after 3 days by coulter counting method	[PMID: 28682067]
HEL	CC₅₀	242 μM Compound: Brivudine	Cytotoxicity against HEL cells assessed as reduction in cell growth after 3 days by coulter counter method Cytotoxicity against HEL cells assessed as reduction in cell growth after 3 days by coulter counter method	[PMID: 28757102]
HEL	CC₅₀	>300 μM Compound: BVDU	Cytotoxicity against HEL cells assessed as reduction in cell viability after 3 days by coulter counting method Cytotoxicity against HEL cells assessed as reduction in cell viability after 3 days by coulter counting method	[PMID: 29268134]
HEL	CC₅₀	>300 μM Compound: Brivudine	Cytostatic activity against HEL cells after 3 days by Coulter counting method Cytostatic activity against HEL cells after 3 days by Coulter counting method	[PMID: 29407990]
HEL	CC₅₀	>300 μM Compound: Brivudin	Cytostatic activity against HEL cells after 3 days by Coulter counting method Cytostatic activity against HEL cells after 3 days by Coulter counting method	[PMID: 29550734]
HEL	CC₅₀	>300 μM Compound: Brivudine	Cytotoxicity against HEL cells assessed as reduction in cell viability after 3 days by coulter counting method Cytotoxicity against HEL cells assessed as reduction in cell viability after 3 days by coulter counting method	[PMID: 29670705]
HEL	CC₅₀	>300 μM Compound: Brivudine	Cytostatic activity against human HEL cells after 3 days by coulter counter method Cytostatic activity against human HEL cells after 3 days by coulter counter method	[PMID: 29945100]
HEL	EC₅₀	>250 μM Compound: Brivudin	Antiviral activity against acyclovir-resistant thymidine kinase negative Human herpesvirus 1 strain KOS infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay Antiviral activity against acyclovir-resistant thymidine kinase negative Human herpesvirus 1 strain KOS infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay	[PMID: 32214762]
HEL	EC₅₀	>250 μM Compound: Brivudin	Antiviral activity against Vesicular stomatitis virus infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay Antiviral activity against Vesicular stomatitis virus infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay	[PMID: 32214762]
HEL	EC₅₀	0.08 μM Compound: Brivudin	Antiviral activity against Human herpesvirus 1 strain KOS infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay Antiviral activity against Human herpesvirus 1 strain KOS infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay	[PMID: 32214762]
HEL	EC₅₀	150 μM Compound: Brivudin	Antiviral activity against Human herpesvirus 2 strain G infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay Antiviral activity against Human herpesvirus 2 strain G infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay	[PMID: 32214762]
HEL	EC₅₀	29 μM Compound: Brivudin	Antiviral activity against Vaccinia virus infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay Antiviral activity against Vaccinia virus infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay	[PMID: 32214762]
HEL	CC₅₀	>300 μM Compound: Brivudin	Cytotoxicity against human HEL cells assessed as reduction in cell proliferation incubated for 3 days by Coulter counter method Cytotoxicity against human HEL cells assessed as reduction in cell proliferation incubated for 3 days by Coulter counter method	[PMID: 32676147]
HEL	EC₅₀	0.089 μM Compound: Brivudin	Antiviral activity against thymidine kinase positive Varicella zoster virus OKA infected in human HEL cells assessed as reduction in plaque formation measured after 5 days Antiviral activity against thymidine kinase positive Varicella zoster virus OKA infected in human HEL cells assessed as reduction in plaque formation measured after 5 days	[PMID: 32676147]
HEL	EC₅₀	0.18 μM Compound: Brivudin	Antiviral activity against thymidine kinase deficient Varicella zoster virus 07-1 infected in human HEL cells assessed as reduction in plaque formation measured after 5 days Antiviral activity against thymidine kinase deficient Varicella zoster virus 07-1 infected in human HEL cells assessed as reduction in plaque formation measured after 5 days	[PMID: 32676147]
HEL	CC₅₀	>300 μM Compound: Brivudin	Cytotoxicity against human HEL cells assessed as reduction in cell growth incubated for 3 days by coulter counter method Cytotoxicity against human HEL cells assessed as reduction in cell growth incubated for 3 days by coulter counter method	[PMID: 33039724]
HEL	CC₅₀	>300 μM Compound: Brivudin	Cytotoxicity against human HEL cells assessed as reduce in cell growth incubated for 3 days by coulter counter analysis Cytotoxicity against human HEL cells assessed as reduce in cell growth incubated for 3 days by coulter counter analysis	[PMID: 33479570]
HEL	CC₅₀	>300 μM Compound: Brivudine	Cytotoxicity against human HEL cells assessed as reduction in cell viability measured after 3 days by beckman coulter counting method Cytotoxicity against human HEL cells assessed as reduction in cell viability measured after 3 days by beckman coulter counting method	[PMID: 33894564]
HEL	CC₅₀	>300 μM Compound: Brivudine	Cytotoxicity against human HEL cells assessed as reduction in cell growth measured after 3 days by coulter counting method Cytotoxicity against human HEL cells assessed as reduction in cell growth measured after 3 days by coulter counting method	[PMID: 35754374]
HEL	CC₅₀	>150 μM Compound: Brivudine	Cytostatic activity against human HEL cells assessed as reduction in cell growth measured after 24 hrs Cytostatic activity against human HEL cells assessed as reduction in cell growth measured after 24 hrs	[PMID: 38643669]
HEL	CC₅₀	>50 μg/mL Compound: BVDU	Tested for the cytotoxic concentration, required to reduce cell growth by 50% in human embryonic lung (HEL) cells. Tested for the cytotoxic concentration, required to reduce cell growth by 50% in human embryonic lung (HEL) cells.	[PMID: 7877148]
HEL	IC₅₀	>100 μg/mL Compound: BVDU	Tested for the inhibitory concentration required to reduce cytomegalovirus (CMV) strain AD-169 plaque formation by 50%. Tested for the inhibitory concentration required to reduce cytomegalovirus (CMV) strain AD-169 plaque formation by 50%.	[PMID: 7877148]
HEL	IC₅₀	>100 μg/mL Compound: BVDU	Tested for the inhibitory concentration required to reduce cytomegalovirus (CMV) strain Davis plaque formation by 50%. Tested for the inhibitory concentration required to reduce cytomegalovirus (CMV) strain Davis plaque formation by 50%.	[PMID: 7877148]
HEL	IC₅₀	0.0015 μg/mL Compound: BVDU	Tested for the inhibitory concentration required to reduce TK+ Varicella-Zoster virus (TK+ VZV) strain YS plaque formation by 50% Tested for the inhibitory concentration required to reduce TK+ Varicella-Zoster virus (TK+ VZV) strain YS plaque formation by 50%	[PMID: 7877148]
HEL	IC₅₀	30 μg/mL Compound: BVDU	Tested for the inhibitory concentration required to reduce thymidine kinase deficient Varicella-Zoster virus (TK- VZV) strain YS/R plaque formation by 50%. Tested for the inhibitory concentration required to reduce thymidine kinase deficient Varicella-Zoster virus (TK- VZV) strain YS/R plaque formation by 50%.	[PMID: 7877148]
HEL	IC₅₀	8 μg/mL Compound: BVDU	Tested for the inhibitory concentration required to reduce thymidine kinase deficient Varicella-Zoster virus (TK- VZV) strain 07/1 plaque formation by 50%. Tested for the inhibitory concentration required to reduce thymidine kinase deficient Varicella-Zoster virus (TK- VZV) strain 07/1 plaque formation by 50%.	[PMID: 7877148]
HEL	IC₅₀	0.0007 μg/mL Compound: BVDU	Tested for the inhibitory concentration required to reduce TK+ Varicella-Zoster virus (TK+ VZV) strain OKA plaque formation by 50%. Tested for the inhibitory concentration required to reduce TK+ Varicella-Zoster virus (TK+ VZV) strain OKA plaque formation by 50%.	[PMID: 7877148]
HEL	IC₅₀	0.7 ng/mL Compound: BVDU	Tested for the inhibitory concentration required to reduce TK+ Varicella-Zoster virus (TK+ VZV) strain OKA plaque formation by 50%. Tested for the inhibitory concentration required to reduce TK+ Varicella-Zoster virus (TK+ VZV) strain OKA plaque formation by 50%.	[PMID: 7877148]
HEL	IC₅₀	>20 μg/mL Compound: brivudin	Anti-VZV activity against YS/R TK- in HEL cells Anti-VZV activity against YS/R TK- in HEL cells	[PMID: 9836626]
HEL	IC₅₀	>50 μg/mL Compound: brivudin	Anti-VZV activity against 07/1 TK- in HEL cells Anti-VZV activity against 07/1 TK- in HEL cells	[PMID: 9836626]
HEL	IC₅₀	0.002 μg/mL Compound: brivudin	Anti-VZV activity against YS TK+ in HEL cells Anti-VZV activity against YS TK+ in HEL cells	[PMID: 9836626]
HEL	IC₅₀	0.0009 μg/mL Compound: brivudin	Anti-VZV activity against OKA strain TK+ in HEL cells Anti-VZV activity against OKA strain TK+ in HEL cells	[PMID: 9836626]
HEL	IC₅₀	0.9 ng/mL Compound: brivudin	Anti-VZV activity against OKA strain TK+ in HEL cells Anti-VZV activity against OKA strain TK+ in HEL cells	[PMID: 9836626]
HEL	EC₅₀	>250 μM Compound: Brivudin	Antiviral activity against acyclovir-resistant TK-deficient Hepres simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay Antiviral activity against acyclovir-resistant TK-deficient Hepres simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay	10.1007/s00044-009-9248-y
HEL	EC₅₀	>250 μM Compound: Brivudin	Antiviral activity against Vesicular stomatitis virus infected HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay Antiviral activity against Vesicular stomatitis virus infected HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay	10.1007/s00044-009-9248-y
HEL	EC₅₀	0.08 μM Compound: Brivudin	Antiviral activity against Human herpesvirus 1 strain KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay Antiviral activity against Human herpesvirus 1 strain KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay	10.1007/s00044-009-9248-y
HEL	EC₅₀	10 μM Compound: Brivudin	Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay	10.1007/s00044-009-9248-y
HEL	EC₅₀	126 μM Compound: Brivudin	Antiviral activity against Human herpesvirus 2 strain G infected HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay Antiviral activity against Human herpesvirus 2 strain G infected HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay	10.1007/s00044-009-9248-y
HEL	CC₅₀	173 μg/mL Compound: Brivudine	Cytotoxicity against HEL Cytotoxicity against HEL	10.1007/s00044-011-9776-0
HEL	EC₅₀	0.0093 μg/mL Compound: Brivudine	Antiviral activity against thymidine kinase-positive Human herpesvirus 3 infected in HEL cells assessed as inhibition of viral plaque formation Antiviral activity against thymidine kinase-positive Human herpesvirus 3 infected in HEL cells assessed as inhibition of viral plaque formation	10.1007/s00044-011-9776-0
HEL	EC₅₀	20 μg/mL Compound: Brivudine	Antiviral activity against thymidine kinase-deficient Human herpesvirus 3 infected in HEL cells assessed as inhibition of viral plaque formation Antiviral activity against thymidine kinase-deficient Human herpesvirus 3 infected in HEL cells assessed as inhibition of viral plaque formation	10.1007/s00044-011-9776-0
HEL	CC₅₀	150 μg/mL Compound: BVDU	Cytotoxic concentration required to reduce cell growth HEL cells (after 3 days) by 50 % Cytotoxic concentration required to reduce cell growth HEL cells (after 3 days) by 50 %	10.1016/0960-894X(95)00278-2
HEL	IC₅₀	>50 μg/mL Compound: BVDU	Evaluated in vitro for antiviral activity in human embryonic lung (HEL) cell cultures against TK- Varicella-Zoster virus (VZV) strain YS/R Evaluated in vitro for antiviral activity in human embryonic lung (HEL) cell cultures against TK- Varicella-Zoster virus (VZV) strain YS/R	10.1016/0960-894X(95)00278-2
HEL	IC₅₀	0.002 μg/mL Compound: BVDU	Evaluated in vitro for antiviral activity in human embryonic lung (HEL) cell cultures against Varicella-Zoster virus (VZV) strain YS Evaluated in vitro for antiviral activity in human embryonic lung (HEL) cell cultures against Varicella-Zoster virus (VZV) strain YS	10.1016/0960-894X(95)00278-2
HEL	IC₅₀	5 μg/mL Compound: BVDU	Evaluated in vitro for antiviral activity in human embryonic lung (HEL) cell cultures against herpes simplex virus type 1 (HSV-1) TK- strain 07/1 Evaluated in vitro for antiviral activity in human embryonic lung (HEL) cell cultures against herpes simplex virus type 1 (HSV-1) TK- strain 07/1	10.1016/0960-894X(95)00278-2
HEL	IC₅₀	0.0008 μg/mL Compound: BVDU	Evaluated in vitro for antiviral activity in human embryonic lung (HEL) cell cultures against TK+ VZV strain OKA Evaluated in vitro for antiviral activity in human embryonic lung (HEL) cell cultures against TK+ VZV strain OKA	10.1016/0960-894X(95)00278-2
HEL	IC₅₀	0.8 ng/mL Compound: BVDU	Evaluated in vitro for antiviral activity in human embryonic lung (HEL) cell cultures against TK+ VZV strain OKA Evaluated in vitro for antiviral activity in human embryonic lung (HEL) cell cultures against TK+ VZV strain OKA	10.1016/0960-894X(95)00278-2
HEL 299	CC₅₀	>100 μM Compound: BVDU	Cytotoxicity against human HEL 299 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter96 Aqueous One Solution cell proliferation assay Cytotoxicity against human HEL 299 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter96 Aqueous One Solution cell proliferation assay	[PMID: 37252100]
HeLa	CC₅₀	>500 μM Compound: Brivudin	Cytotoxicity against HeLa cells Cytotoxicity against HeLa cells	[PMID: 17181162]
HeLa	EC₅₀	>500 μM Compound: Brivudin	Antiviral activity against Coxsackie B4 virus in HeLa cells Antiviral activity against Coxsackie B4 virus in HeLa cells	[PMID: 17181162]
HeLa	EC₅₀	>500 μM Compound: Brivudin	Antiviral activity against RSV in HeLa cells Antiviral activity against RSV in HeLa cells	[PMID: 17181162]
HeLa	EC₅₀	>400 μg/mL Compound: brivudin	Antiviral activity against coxsackie B4 virus in HeLa cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against coxsackie B4 virus in HeLa cells assessed as inhibition of virus-induced cytopathicity	[PMID: 17298047]
HeLa	EC₅₀	>400 μg/mL Compound: brivudin	Antiviral activity against RSV Long in HeLa cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against RSV Long in HeLa cells assessed as inhibition of virus-induced cytopathicity	[PMID: 17298047]
HeLa	EC₅₀	>400 μg/mL Compound: brivudin	Antiviral activity against VSV in HeLa cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against VSV in HeLa cells assessed as inhibition of virus-induced cytopathicity	[PMID: 17298047]
HeLa	EC₅₀	>250 μM Compound: brivudin	Antiviral activity against coxsackie B4 virus in HeLa cells assessed as reduction of virus plaque formation after 7 days Antiviral activity against coxsackie B4 virus in HeLa cells assessed as reduction of virus plaque formation after 7 days	[PMID: 17539622]
HeLa	EC₅₀	>200 μg/mL Compound: brivudin	Antiviral activity against Coxsackie virus B4 in HeLa cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against Coxsackie virus B4 in HeLa cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17948980]
HeLa	EC₅₀	>200 μg/mL Compound: brivudin	Antiviral activity against RSV in HeLa cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against RSV in HeLa cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17948980]
HeLa	EC₅₀	200 μg/mL Compound: brivudin	Antiviral activity against VSV in HeLa cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against VSV in HeLa cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17948980]
HeLa	EC₅₀	>400 μg/mL Compound: Brivudin	Antiviral activity against RSV infected in human HeLa cell assessed as inhibition of virus-induced cytopathicity Antiviral activity against RSV infected in human HeLa cell assessed as inhibition of virus-induced cytopathicity	[PMID: 20377249]
HeLa	EC₅₀	>400 μg/mL Compound: Brivudin	Antiviral activity against VSV infected in human HeLa cell assessed as inhibition of virus-induced cytopathicity Antiviral activity against VSV infected in human HeLa cell assessed as inhibition of virus-induced cytopathicity	[PMID: 20377249]
HeLa	CC₅₀	362 μM Compound: Brivudin	Cytotoxicity against human HeLa cells assessed as cell viability by colorimetric formazan-based MTS assay Cytotoxicity against human HeLa cells assessed as cell viability by colorimetric formazan-based MTS assay	[PMID: 22459876]
HeLa	IC₅₀	0.2 μM Compound: BVdU	Cytostatic activity against thymidine kinase deficient human HeLa cells after 3 days by cell counting method Cytostatic activity against thymidine kinase deficient human HeLa cells after 3 days by cell counting method	[PMID: 27818111]
HeLa	IC₅₀	160 μM Compound: BVdU	Cytostatic activity against human HeLa cells after 3 days by cell counting method Cytostatic activity against human HeLa cells after 3 days by cell counting method	[PMID: 27818111]
HeLa	CC₅₀	>400 μg/mL Compound: brivudin	Cytotoxic concentration required to cause microscopically detectable alteration of normal cell morphology of HeLa cells Cytotoxic concentration required to cause microscopically detectable alteration of normal cell morphology of HeLa cells	[PMID: 8709116]
Jurkat	EC₅₀	>100 μM Compound: 6; BVDU; Brivudin	Cytotoxicity against human Jurkat cells assessed as reduction in cell viability after 72 hrs by MTS assay Cytotoxicity against human Jurkat cells assessed as reduction in cell viability after 72 hrs by MTS assay	[PMID: 27032331]
L1210	IC₅₀	38 μM Compound: BVdU	Cytostatic activity against mouse L1210 cells after 2 days by cell counting method Cytostatic activity against mouse L1210 cells after 2 days by cell counting method	[PMID: 27818111]
L1210	IC₅₀	9.6 μM Compound: BVdU	Cytostatic activity against thymidine kinase deficient mouse L1210 cells after 2 days by cell counting method Cytostatic activity against thymidine kinase deficient mouse L1210 cells after 2 days by cell counting method	[PMID: 27818111]
MRC5	IC₅₀	<1 μM Compound: BVDU	Inhibitory activity against varicella zoster virus (VZV) strain G31 in MRC-5 cells. Inhibitory activity against varicella zoster virus (VZV) strain G31 in MRC-5 cells.	[PMID: 8576922]
MRC5	IC₅₀	>100 μM Compound: BVDU	Inhibitory activity against human cytomegalovirus (HCMV) strain AD169 in MRC-5 cells. Inhibitory activity against human cytomegalovirus (HCMV) strain AD169 in MRC-5 cells.	[PMID: 8576922]
OST	IC₅₀	>=250 μM Compound: brivudin	Inhibition of proliferation of thymidine kinase deficient OST cells Inhibition of proliferation of thymidine kinase deficient OST cells	[PMID: 17518459]
P3HR-1	CC₅₀	225 μM Compound: 1	Cytotoxic concentration for the inhibition of P3HR-1 cell growth Cytotoxic concentration for the inhibition of P3HR-1 cell growth	[PMID: 12408726]
P3HR-1	EC₅₀	>300 μM Compound: 1	Effective concentration for the inhibition of Epstein-Barr virus EBV-DNA synthesis in human lymphoblastoid P3HR-1 cells Effective concentration for the inhibition of Epstein-Barr virus EBV-DNA synthesis in human lymphoblastoid P3HR-1 cells	[PMID: 12408726]
PC-3	EC₅₀	>100 μM Compound: 6; BVDU; Brivudin	Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 72 hrs by MTS assay Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 72 hrs by MTS assay	[PMID: 27032331]
Ramos	EC₅₀	>100 μM Compound: 6; BVDU; Brivudin	Cytotoxicity against human Ramos cells assessed as reduction in cell viability after 72 hrs by MTS assay Cytotoxicity against human Ramos cells assessed as reduction in cell viability after 72 hrs by MTS assay	[PMID: 27032331]
U-87MG ATCC	EC₅₀	>100 μM Compound: 6; BVDU; Brivudin	Cytotoxicity against human U87 cells assessed as reduction in cell viability after 72 hrs by MTS assay Cytotoxicity against human U87 cells assessed as reduction in cell viability after 72 hrs by MTS assay	[PMID: 27032331]
Vero	EC₅₀	>150 μM Compound: BVDU	Inhibition of plaque formation in monolayers of HSV-1 KOSSB(TK-) Vero cells by 50% Inhibition of plaque formation in monolayers of HSV-1 KOSSB(TK-) Vero cells by 50%	[PMID: 11585457]
Vero	EC₅₀	>150 μM Compound: BVDU	Inhibition of viral cytopathic effect in infected human foreskin fibroblast cell in monolayers of HSV-2 AD Vero cells by 50% Inhibition of viral cytopathic effect in infected human foreskin fibroblast cell in monolayers of HSV-2 AD Vero cells by 50%	[PMID: 11585457]
Vero	EC₅₀	0.003 μM Compound: BVDU	Inhibition of viral cytopathic effect in infected human foreskin fibroblast cell in monolayers of VZV Ellen Vero cells by 50% Inhibition of viral cytopathic effect in infected human foreskin fibroblast cell in monolayers of VZV Ellen Vero cells by 50%	[PMID: 11585457]
Vero	EC₅₀	1.5 μM Compound: BVDU	Inhibition of plaque formation in monolayers of HSV-1 KOS Vero cells by 50% Inhibition of plaque formation in monolayers of HSV-1 KOS Vero cells by 50%	[PMID: 11585457]
Vero	EC₅₀	2.7 μM Compound: BVDU	Inhibition of plaque formation in monolayers of HSV-1 E-377 Vero cells by 50% Inhibition of plaque formation in monolayers of HSV-1 E-377 Vero cells by 50%	[PMID: 11585457]
Vero	CC₅₀	>500 μM Compound: Brivudin	Cytotoxicity against Vero cells Cytotoxicity against Vero cells	[PMID: 17181162]
Vero	EC₅₀	>500 μM Compound: Brivudin	Antiviral activity against para influenza 3 virus in Vero cells Antiviral activity against para influenza 3 virus in Vero cells	[PMID: 17181162]
Vero	EC₅₀	>500 μM Compound: Brivudin	Antiviral activity against Punta Toro virus in Vero cells Antiviral activity against Punta Toro virus in Vero cells	[PMID: 17181162]
Vero	EC₅₀	>500 μM Compound: Brivudin	Antiviral activity against reovirus 1 in Vero cells Antiviral activity against reovirus 1 in Vero cells	[PMID: 17181162]
Vero	EC₅₀	>500 μM Compound: Brivudin	Antiviral activity against Sindbis virus in Vero cells Antiviral activity against Sindbis virus in Vero cells	[PMID: 17181162]
Vero	EC₅₀	>400 μg/mL Compound: brivudin	Antiviral activity against coxsackie B4 virus in Vero cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against coxsackie B4 virus in Vero cells assessed as inhibition of virus-induced cytopathicity	[PMID: 17298047]
Vero	EC₅₀	>400 μg/mL Compound: brivudin	Antiviral activity against parainfluenza3 virus in Vero cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against parainfluenza3 virus in Vero cells assessed as inhibition of virus-induced cytopathicity	[PMID: 17298047]
Vero	EC₅₀	>400 μg/mL Compound: brivudin	Antiviral activity against punta toro virus in Vero cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against punta toro virus in Vero cells assessed as inhibition of virus-induced cytopathicity	[PMID: 17298047]
Vero	EC₅₀	>400 μg/mL Compound: brivudin	Antiviral activity against reovirus1 in Vero cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against reovirus1 in Vero cells assessed as inhibition of virus-induced cytopathicity	[PMID: 17298047]
Vero	EC₅₀	>400 μg/mL Compound: brivudin	Antiviral activity against sindbis virus in Vero cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against sindbis virus in Vero cells assessed as inhibition of virus-induced cytopathicity	[PMID: 17298047]
Vero	CC₅₀	>600 μM Compound: BVdU	Cytotoxicity against african green monkey Vero cells after 2 days Cytotoxicity against african green monkey Vero cells after 2 days	[PMID: 17438061]
Vero	EC₅₀	>300 μM Compound: BVdU	Antiviral activity against Herpes B virus 24105 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs Antiviral activity against Herpes B virus 24105 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs	[PMID: 17438061]
Vero	EC₅₀	>300 μM Compound: BVdU	Antiviral activity against Herpes B virus 32425 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs Antiviral activity against Herpes B virus 32425 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs	[PMID: 17438061]
Vero	EC₅₀	0.12 μM Compound: BVdU	Antiviral activity against Herpes simplex virus 1 F infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs Antiviral activity against Herpes simplex virus 1 F infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs	[PMID: 17438061]
Vero	EC₅₀	>250 μM Compound: brivudin	Antiviral activity against parainfluenza 3 virus in Vero cells assessed as reduction of virus plaque formation after 7 days Antiviral activity against parainfluenza 3 virus in Vero cells assessed as reduction of virus plaque formation after 7 days	[PMID: 17539622]
Vero	EC₅₀	>250 μM Compound: brivudin	Antiviral activity against Punta Toro virus in Vero cells assessed as reduction of virus plaque formation after 7 days Antiviral activity against Punta Toro virus in Vero cells assessed as reduction of virus plaque formation after 7 days	[PMID: 17539622]
Vero	EC₅₀	>250 μM Compound: brivudin	Antiviral activity against reovirus1 virus in Vero cells assessed as reduction of virus plaque formation after 7 days Antiviral activity against reovirus1 virus in Vero cells assessed as reduction of virus plaque formation after 7 days	[PMID: 17539622]
Vero	EC₅₀	>250 μM Compound: brivudin	Antiviral activity against sindbis virus in Vero cells assessed as reduction of virus plaque formation after 7 days Antiviral activity against sindbis virus in Vero cells assessed as reduction of virus plaque formation after 7 days	[PMID: 17539622]
Vero	EC₅₀	>200 μg/mL Compound: brivudin	Antiviral activity against Parainfluenza 3 in Vero cells reduction of virus-induced cytopathogenicity after 4 days Antiviral activity against Parainfluenza 3 in Vero cells reduction of virus-induced cytopathogenicity after 4 days	[PMID: 17948980]
Vero	EC₅₀	>200 μg/mL Compound: brivudin	Antiviral activity against Punta Toro virus in Vero cells reduction of virus-induced cytopathogenicity after 4 days Antiviral activity against Punta Toro virus in Vero cells reduction of virus-induced cytopathogenicity after 4 days	[PMID: 17948980]
Vero	EC₅₀	>200 μg/mL Compound: brivudin	Antiviral activity against Reovirus 1 in Vero cells reduction of virus-induced cytopathogenicity after 4 days Antiviral activity against Reovirus 1 in Vero cells reduction of virus-induced cytopathogenicity after 4 days	[PMID: 17948980]
Vero	EC₅₀	>200 μg/mL Compound: brivudin	Antiviral activity against Sindbis virus in Vero cells reduction of virus-induced cytopathogenicity after 4 days Antiviral activity against Sindbis virus in Vero cells reduction of virus-induced cytopathogenicity after 4 days	[PMID: 17948980]
Vero	EC₅₀	>200 μg/mL Compound: brivudin	Antiviral activity against Coxsackie virus B4 in Vero cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against Coxsackie virus B4 in Vero cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17948980]
Vero	EC₅₀	>400 μg/mL Compound: Brivudin	Antiviral activity against Parainfluenza virus 3 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Parainfluenza virus 3 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity	[PMID: 20377249]
Vero	EC₅₀	>400 μg/mL Compound: Brivudin	Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity	[PMID: 20377249]
Vero	EC₅₀	>400 μg/mL Compound: Brivudin	Antiviral activity against Reovirus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Reovirus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity	[PMID: 20377249]
Vero	EC₅₀	>400 μg/mL Compound: Brivudin	Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity	[PMID: 20377249]
Vero	ED₅₀	0.07 μM Compound: BrVdu	In vitro antiviral activity was determined by plaque-reduction assay in HSV-1(strain 2931) infected Vero cell monolayers In vitro antiviral activity was determined by plaque-reduction assay in HSV-1(strain 2931) infected Vero cell monolayers	[PMID: 6317862]
Vero	ED₅₀	12.95 μM Compound: BrVdu	In vitro antiviral activity was determined by plaque-reduction assay in HSV-2 (strain G) infected Vero cell monolayers In vitro antiviral activity was determined by plaque-reduction assay in HSV-2 (strain G) infected Vero cell monolayers	[PMID: 6317862]
Vero	ED₅₀	0.3 μM Compound: BVDU	Antiviral activity against HSV-1 (Herpes simplex virus) in vero cells Antiviral activity against HSV-1 (Herpes simplex virus) in vero cells	[PMID: 8289203]
Vero	ED₅₀	6.8 μM Compound: BVDU	Antiviral activity against HSV-2 (Herpes simplex virus) in vero cells Antiviral activity against HSV-2 (Herpes simplex virus) in vero cells	[PMID: 8289203]
Vero	IC₅₀	1.4 μM Compound: BVDU	Inhibitory activity against herpes simplex virus type 1 (HSV-1) strain SC16 in Vero cells. Inhibitory activity against herpes simplex virus type 1 (HSV-1) strain SC16 in Vero cells.	[PMID: 8576922]
Vero	IC₅₀	10 μM Compound: BVDU	Inhibitory activity against herpes simplex virus type 2 (HSV 2) strain 186 in Vero cells. Inhibitory activity against herpes simplex virus type 2 (HSV 2) strain 186 in Vero cells.	[PMID: 8576922]
Vero	CC₅₀	>400 μg/mL Compound: brivudin	Cytotoxic concentration required to cause microscopically detectable alteration of normal cell morphology of Vero cells Cytotoxic concentration required to cause microscopically detectable alteration of normal cell morphology of Vero cells	[PMID: 8709116]
Vero	EC₅₀	>400 μg/mL Compound: BVDU	Effective concentration required to reduce coxsackie virus B4-induced cytopathicity in vero cells Effective concentration required to reduce coxsackie virus B4-induced cytopathicity in vero cells	[PMID: 9171871]
Vero	EC₅₀	>400 μg/mL Compound: BVDU	Effective concentration required to reduce parainfluenza-3-induced cytopathicity in vero cells Effective concentration required to reduce parainfluenza-3-induced cytopathicity in vero cells	[PMID: 9171871]
Vero	EC₅₀	>400 μg/mL Compound: BVDU	Effective concentration required to reduce reovirus-1-induced cytopathicity in vero cells Effective concentration required to reduce reovirus-1-induced cytopathicity in vero cells	[PMID: 9171871]
Vero	EC₅₀	>400 μg/mL Compound: BVDU	Effective concentration required to reduce sindbis virus-induced cytopathicity in vero cells Effective concentration required to reduce sindbis virus-induced cytopathicity in vero cells	[PMID: 9171871]
Vero	EC₅₀	>400 μg/mL Compound: BVDU	Effective concentration required to reduce vesicular stomatitis virus (VSV)-induced cytopathicity in vero cells Effective concentration required to reduce vesicular stomatitis virus (VSV)-induced cytopathicity in vero cells	[PMID: 9171871]

In Vitro

Brivudine is an analog of thymidine, and is incorporated into the viral DNA. It blocks the action of DNA polymerases, thus inhibiting viral replication. It has a stronger antiviral effect against the varicella-zoster virus compared with reference compounds such as aciclovir or penciclovir^[1]. It has high, selective activity against varicella zoster virus (VZV), inhibiting VZV replication, possibly through competitive inhibition of viral DNA polymerase, or by acting as an alternative substrate to deoxythymidine triphosphate, causing viral DNA strand breakage^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

At a dose of 125 mg once daily, brivudine has proved to be superior to aciclovir with respect to reducing the period of new blister production, and has shortened the duration of post-herpetic neuralgia^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 69304-47-8
Appearance Solid
Molecular Weight 333.14
Formula C₁₁H₁₃BrN₂O₅
Color White to off-white
SMILES

OC[C@@H]1[C@H](C[C@H](N2C(NC(C(/C=C/Br)=C2)=O)=O)O1)O
Synonyms

Bromovinyldeoxyuridine; BVDU
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (2)

All

Sort by:

Journal Impact Factor

EMBO Mol Med

Intestinal Apc-inactivation induces HSP25 dependency. [Abstract]

2022 Dec 7;14(12):e16194. PMID: 36321561
Anal Chem

Exposome-Scale Investigation of Cl-/Br-Containing Chemicals Using High-Resolution Mass Spectrometry, Multistage Machine Learning, and Cloud Computing. [Abstract]

2025 Jun 3;97(21):11099-11109. PMID: 40401576

Solvent & Solubility

In Vitro:

DMSO : 200 mg/mL (600.35 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.0017 mL

15.0087 mL

30.0174 mL

5 mM

0.6003 mL

3.0017 mL

6.0035 mL

10 mM

0.3002 mL

1.5009 mL

3.0017 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 10 mg/mL (30.02 mM); Clear solution

This protocol yields a clear solution of ≥ 10 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (100.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 10 mg/mL (30.02 mM); Clear solution

This protocol yields a clear solution of ≥ 10 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (100.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 10 mg/mL (30.02 mM); Clear solution

This protocol yields a clear solution of ≥ 10 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (100.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (274 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Rabasseda X, et al. Brivudine: a herpes virostatic with rapid antiviral activity and once-daily dosing. Drugs Today (Barc). 2003 May;39(5):359-71. [Content Brief]

[2]. Keam SJ, et al. Brivudin (bromovinyl deoxyuridine). Drugs. 2004;64(18):2091-7; discussion 2098-9. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.0017 mL	15.0087 mL	30.0174 mL	75.0435 mL
	5 mM	0.6003 mL	3.0017 mL	6.0035 mL	15.0087 mL
	10 mM	0.3002 mL	1.5009 mL	3.0017 mL	7.5044 mL
	15 mM	0.2001 mL	1.0006 mL	2.0012 mL	5.0029 mL
	20 mM	0.1501 mL	0.7504 mL	1.5009 mL	3.7522 mL
	25 mM	0.1201 mL	0.6003 mL	1.2007 mL	3.0017 mL
	30 mM	0.1001 mL	0.5003 mL	1.0006 mL	2.5015 mL
	40 mM	0.0750 mL	0.3752 mL	0.7504 mL	1.8761 mL
	50 mM	0.0600 mL	0.3002 mL	0.6003 mL	1.5009 mL
	60 mM	0.0500 mL	0.2501 mL	0.5003 mL	1.2507 mL
	80 mM	0.0375 mL	0.1876 mL	0.3752 mL	0.9380 mL
	100 mM	0.0300 mL	0.1501 mL	0.3002 mL	0.7504 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Brivudine

Anti-Infection Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Antiviral Compound Library

Drug Repurposing Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

FDA Approved & Pharmacopeial Drug Library

Rare Diseases Drug Library

FDA-Approved Anticancer Drug Library

Off-patent Drug Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Brivudine

Biological Activity

Chemical Information

Publications (2)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Brivudine

Anti-Infection Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Antiviral Compound Library

Drug Repurposing Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

FDA Approved & Pharmacopeial Drug Library

Rare Diseases Drug Library

FDA-Approved Anticancer Drug Library

Off-patent Drug Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Brivudine

Biological Activity

Chemical Information

Publications (2)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Brivudine Related Classifications

HY-13578 Related Classifications